Mongoose Bio is developing epigenetically reprogrammed central memory T cells (Tcm) that target highly immunogenic tumor antigens to create long-lasting TCR-T cell therapies for solid tumors. This approach addresses the limitations of existing therapies by enhancing T cell persistence and efficacy while minimizing toxicity and the need for high-dose lymphodepletion.
Funding
Funding not disclosed
Founders
Product
Problem
Existing T-cell therapies for solid tumors face limitations in T-cell persistence, efficacy, and toxicity, often requiring high-dose lymphodepletion and showing limited regenerative capacity. Current approaches struggle with antigen loss and are difficult to combine with other treatment strategies.
Solution
Mongoose Bio is developing epigenetically reprogrammed central memory T cells (Tcm) that target highly immunogenic tumor antigens, creating long-lasting TCR-T cell therapies designed to overcome the limitations of existing approaches for solid tumors. By reprogramming Tcm cells, Mongoose Bio aims to enhance T-cell persistence and efficacy while minimizing toxicity and the need for high-dose lymphodepletion. This approach leverages the regenerative capacity of Tcm cells, differentiating it from therapies relying on terminally differentiated Teff and Tex cells. The company's technology targets both extracellular and intracellular targets, addressing antigen loss and enabling easier implementation of combination strategies.
Target Audience
The primary target audience includes patients with common and rare solid tumors who can benefit from more effective and less toxic T-cell therapies, as well as oncology centers and clinicians specializing in adoptive T-cell therapies.
Features
- Epigenetically reprogrammed central memory T cells (Tcm) for enhanced persistence and activity.
- Targeting of highly immunogenic tumor antigens to address a broad range of solid tumors.
- TCR-T cell therapies designed to minimize toxicity and eliminate the need for high-dose lymphodepletion.
- Proprietary technology to extend the life of memory T cells specifically modified to kill targeted tumor cells.
- Ability to target both extracellular and intracellular antigens, reducing the risk of antigen loss.
- Readily implementable combination strategies with other cancer treatments.